Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Boston Therapeutics Inc (OTC: BTHE).

Full DD Report for BTHE

You must become a subscriber to view this report.


Recent News from (OTC: BTHE)

Boston Therapeutics Phase I Study Results Accepted for Publication
LAWRENCE, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics (OTCQB:BTHE) is pleased to announce the acceptance of the Phase I proof of concept study of the pharmacology of BTI-320 prior to high glycemic meals for publication in the Journal of Clinical Pharmacology in Drug Developm...
Source: GlobeNewswire
Date: May, 10 2018 13:04
Boston Therapeutics Corporate Call Transcript Posted
LAWRENCE, Mass., April 27, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “ Company ” or “ BTI ”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics for the potential treatment of diabetes and related complic...
Source: GlobeNewswire
Date: April, 27 2018 12:01
Boston Therapeutics to Hold Business Update Conference Call Wednesday, April 18, 2018 at 5:00 p.m. ET
LAWRENCE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “ Company ” or “ BTI ”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics for the potential treatment of diabetes and related complic...
Source: GlobeNewswire
Date: April, 16 2018 11:35
Boston Therapeutics Announces Letter of Intent to Acquire Pennsylvania-based Medical Technology Associates II (MTA2)
LAWRENCE, Mass., April 12, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “ Company ” or “ BTI ”) (OTCQB:BTHE) is pleased to announce that it has entered into a non-binding letter of intent dated April 11, 2018 (the “ Letter of Intent ”) wit...
Source: GlobeNewswire
Date: April, 12 2018 09:35
Boston Therapeutics Awarded Key European Patent
LAWRENCE, Mass., April 06, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics (the “ Company ” or “ BTI ”) (OTCQB:BTHE) is pleased to announce that it has won a patent position argued with the European Patent and Trademark Office this week.  The patent has claims ...
Source: GlobeNewswire
Date: April, 06 2018 09:00
Boston Therapeutics Engages Medical and FDA Experts: Launching New Strategic Initiatives
LAWRENCE, Mass., March 29, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, an innovator in the design, development and commercialization of novel treatments for diabetes and its related complications, is pleased to announce the addition of two more accomplished and renowned scientists and cli...
Source: GlobeNewswire
Date: March, 29 2018 13:10
Boston Therapeutics Creates New Scientific Advisory Board
LAWRENCE, Mass., March 27, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, an innovator in the design, development and early commercialization of novel therapeutics for the potential treatment of diabetes and related complications, is pleased to announce the addition of three accomplished and...
Source: GlobeNewswire
Date: March, 27 2018 11:48
Boston Therapeutics Joins the Biotechnology Innovation Organization (BIO)
LAWRENCE, Mass., March 08, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc announces their new participation in MassBIO, an unparalleled network of innovative companies and industry thought leaders dedicated to advancing cutting-edge research and development for patients’ lives imp...
Source: GlobeNewswire
Date: March, 08 2018 11:04
Boston Therapeutics Announces New COO, Loraine V. Upham
LAWRENCE, Mass., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc. announces that Loraine V. Upham will join the team to lead the US operations and drug development effort for the diabetes portfolio. Formerly of Eli Lilly and Merck and Company, Upham brings both large pharmaceutic...
Source: GlobeNewswire
Date: February, 20 2018 09:00
Boston Therapeutics Announces Strategic Acquisition of CureDM
LAWRENCE, Mass., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc. (Boston Therapeutics) announces the acquisition of CureDM Group Holdings, LLC (CureDM), adding a Phase 2-ready drug to their portfolio.  The CureDM islet-growing peptide, HIP2B, has demonstrated clinical effic...
Source: GlobeNewswire
Date: February, 13 2018 09:00

 


About Boston Therapeutics Inc (OTC: BTHE)

Logo for Boston Therapeutics Inc (OTC: BTHE)

Boston Therapeutics, Inc. OTCQB: BTHE , headquartered in Lawrence, MA, is a leader in the field of designing drugs using complex carbohydrates. The Company s product pipeline is focused on developing and commercializing therapeutic molecules for diabetes, including: BTI , a non systemic chewable compound designed to reduce post meal glucose elevation IPOXYN, an injectable anti necrosis drug specifically designed to treat lower limb ischemia and SUGARDOWN R , an OTC dietary supplement designed to lower post meal sugar spike. More information on BTHE is available at www.bostonti.com.

 

Contact Information

 

 

Current Management

  • Carl Rausch / CEO
  • Loraine V. Upham / COO
  • Stephen Spanos / Consultant
  • Conroy Cheng /
  • S. Colin Neill /
  • Carl Rausch /

Current Share Structure

  • Market Cap: $4,230,601 - 03/15/2018
  • Authorized: 200,000,000 - 03/07/2017
  • Issue and Outstanding: 60,437,163 - 11/13/2017
  • Float: 19,337,223 - 10/23/2017

 


Recent Filings from (OTC: BTHE)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: April, 30 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 27 2018
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: February, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 12 2018
All other definitive information statements
Filing Type: DEF 14CFiling Source: edgar
Filing Date: February, 09 2018
Preliminary proxy statement containing all other information
Filing Type: PRE 14CFiling Source: edgar
Filing Date: January, 22 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 13 2017
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: November, 01 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 22 2017

 

 


Daily Technical Chart for (OTC: BTHE)

Daily Technical Chart for (OTC: BTHE)


Stay tuned for daily updates and more on (OTC: BTHE)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BTHE)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BTHE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of BTHE and does not buy, sell, or trade any shares of BTHE. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/